- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Eye on Pharma: Celltrion Seeks to Expand Portfolio After IPO
Celltrion Healthcare, the marketing subsidiary of Celltrion Inc, has secured approximately $886.3 million—well over a previously projected $713 million—in its July initial public offering of 24.6 million primary shares.
Global Capital Asia reports that Celltrion Healthcare, the marketing subsidiary of Celltrion Inc, has secured approximately $886.3 million—well over a previously projected $713 million—in its July initial public offering (IPO) of 24.6 million primary shares.
CEO of Celltrion Healthcare, Kim Man-Hoon, has announced that the Korean biosimilar maker is seeking additional drug candidates as it leverages its newly raised funds to broaden its product portfolio. According to Bio Spectrum Asia, Celltrion’s expansion will include international investment, strategic acquisition, joint ventures, and licensing partnerships with new drug developers as the company expands and capitalizes on its already robust pipeline. “We have plans to launch a major biosimilar every year until 2019,” Kim said.
Kim went on to indicate that among the company’s chief aims is the acquisition of US-based biotechnology companies as Celltrion expands its presence in the lucrative US marketplace. “By taking over US biotech firms, we expect to boost Celltrion Healthcare’s brand awareness and market share,” said Kim.
The biosimilar manufacturer, which announced that it had submitted to the FDA its Biologics License Application (BLA) for a proposed biosimilar rituximab product in June, reports 6 biosimilars currently under development:
- Remsima SC (infliximab for the treatment of rheumatoid arthritis)
- CT-P16 (bevacizumab for the treatment of large intestine cancer)
- CT-P05 (etanercept for the treatment of rheumatoid arthritis)
- CT-P15 (cetuximab for the treatment of colorectal cancer)
- CT-P14 (palivizumab for the treatment of respiratory diseases)
- CTP-17 (adalimumab for the treatment of rheumatoid arthritis).
The company is also developing 5 innovator biologics for influenza, rabies, hepatitis B virus, and others.
The successful IPO is welcome news to the Incheon-based company that, earlier this year, had to delay its offering after local regulators and accountants demanded a comprehensive audit of the company’s accounting practices. In March, the Korean Institute of Certified Public Accountants, a body that reviews the eligibility of firms to offer shares, found that Celltrion Healthcare had overstated its profits by approximately $8.94 million.
While many in the industry feared that the audit would set the biosimilar manufacturer’s IPO back by 6 months or more, Celltrion Healthcare confidently—and correctly—predicted that the process would not have a significant impact on its timeline for launching the IPO.
Celltrion’s stock will begin trading on the Korean market on July 28, and is expected to be the second most valuable company on the Kosdaq index.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
